Article Details
Retrieved on: 2023-12-26 18:25:37
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The cash deal, which adds several experimental therapies to AstraZeneca's portfolio, values Gracell at $2 per ordinary share, or $10 per ADS of ...
Article found on: economictimes.indiatimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here